Skip to content
OpenCapital
Get started

Rapport Therapeutics, Inc. RAPP Cash ratio

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
0.5×+0.1×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
13.7×+10.1×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
10.7×+6.5×
Biohaven logo
BiohavenBHVN
5.3×+4.7×
Septerna, Inc. logo
Septerna, Inc.SEPN
0.9×-18.8×

Other financials

Income statement

See full
Revenue$20.0M—
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%—
Debt / equity0×0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

cash and equivalents/total current liabilities=4.4×

Based on the most recent quarter.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s cash ratio?
Rapport Therapeutics, Inc. (RAPP) reported cash ratio of 4.4× in Q1 2026.
How has Rapport Therapeutics, Inc.'s cash ratio changed year-over-year?
Rapport Therapeutics, Inc.'s cash ratio decreased by 29.0% year-over-year, from 6.1× to 4.4×.
What is the long-term trend for Rapport Therapeutics, Inc.'s cash ratio?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s cash ratio has grown at a -41.1% compound annual growth rate (CAGR), from 8× to 2.8×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.